{"id":"vehicle-to-agn-229666","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4303670","moleculeType":"Small molecule","molecularWeight":"424.57"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"RXR agonists activate retinoid X receptors, which are nuclear receptors involved in regulating gene expression related to inflammation, differentiation, and tissue homeostasis. AGN-229666 is being developed as a topical or systemic agent to treat inflammatory and degenerative conditions by modulating these pathways. The drug is being evaluated in Phase 3 trials, likely for dermatological or ocular indications given Allergan's therapeutic focus.","oneSentence":"AGN-229666 is a selective retinoid X receptor (RXR) agonist that modulates nuclear receptor signaling to reduce inflammation and promote tissue repair.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:51:07.828Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory skin or ocular condition (specific indication not publicly confirmed)"}]},"trialDetails":[{"nctId":"NCT02161146","phase":"PHASE3","title":"AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-06-04","conditions":"Conjunctivitis, Allergic","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Vehicle to AGN-229666","genericName":"Vehicle to AGN-229666","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AGN-229666 is a selective retinoid X receptor (RXR) agonist that modulates nuclear receptor signaling to reduce inflammation and promote tissue repair. Used for Inflammatory skin or ocular condition (specific indication not publicly confirmed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}